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Abstract
The use of left ventricular assist devices (LVAD) provides a treatment strategy for
advanced heart failure patients to prolong life and serve as a mediator (bridge to
transplant) until an organ becomes available in patients considered suitable
candidates for heart transplantation. The use of LVAD therapy is complicated by
the constant risk of bleeding and thrombotic events. We reviewed and analyzed
the effectiveness of our current heparin protocol with respect to overall
anticoagulation and time in therapeutic range (TTR). Our analysis demonstrated
that patients did not achieve therapeutic anticoagulation for at least 24 hours
following initiation of heparin and that only 40% of the time patients were
considered therapeutic. Even after patients achieved a therapeutic activated
plasma thromboplastin time (aPTT) TTR was only approximately 50% with less
than 50% of tests resulting within range. Individual centers should perform
ongoing assessment of effectiveness of individual heparin protocol for LVAD
patients to ensure anticoagulation is optimized in these highly complex patients.
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Introduction
Left ventricular assist devices have become an essential component in heart
failure management.1-5 While heart transplant remains the only definitive therapy
for patients with advanced heart failure (AHF), left ventricular assist device (LVAD)
therapy provides a viable option for patients deemed candidates for transplant or
as destination therapy in ineligible candidates.1-5 Unfortunately, despite significant
advancements in LVAD therapy, its use continues to be complicated by bleeding
risks and pump thrombosis.6-10 The use of anticoagulation therapy following LVAD
implantation remains non-standardized, varying significantly amongst various
centers and continues to evolve with emerging data.10 In 2014, a report
demonstrated an unexpected significant increase in the rate of pump thrombosis
and strokes in patients implanted with the Heartmate II, a continuous-flow LVAD at
three major LVAD programs.11 Unfortunately, the exact etiology for pump
thrombosis was not established but potential causes could relate to changes in
anticoagulation practices, surgical technique, and change in pump design or
manufacturing.
The manufacturers for the Heartware and HeartMate II devices provide
recommendations regarding anticoagulation and antiplatelet therapy but do not
provide strategies to achieve and maintain these parameters.12-13 During the study
period, we utilized the atrial fibrillation (AF)/stroke prophylaxis heparin protocol
following LVAD placement with a therapeutic aPTT range defined as 60-80
seconds. The use of this protocol has not been formally reviewed in this patient
population and the potential risks/benefits remain unclear. With continued concern
surrounding the risk of pump thrombosis and strokes within LVAD patients, our
center wanted to evaluate current systemic intravenous anticoagulation practices
to assess overall management in an effort to reduce the risk for pump thrombosis
and strokes.

Methods
This was a single-center, retrospective descriptive analysis conducted at an
academic medical center. Patients >18 years of age who were implanted or
readmitted with a Heartmate II or Heartware LVAD between January 2013 and
June 2015 were considered for inclusion. Patients were excluded from the
analysis if they were not initiated on the AF/stroke prophylaxis heparin protocol or
if they achieved therapeutic anticoagulation on fixed dose heparin. Additionally,
patients requiring an LVAD exchange were excluded from analyses following
pump exchange but were considered for inclusion at any point prior to the
exchange. The therapeutic range of the AF/stroke prophylaxis protocol was
defined as 60-80 seconds. Adjustments to goal range were considered deviations
from standard therapy and excluded from analysis. Patients initiated on heparin
protocol post-LVAD implantation were analyzed separately than patients
readmitted and started on heparin protocol. In an effort to standardize heparin
management, our institution utilizes adjust body weight
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Heparin initiation time was defined as end anesthesia time until initiation of
heparin, while heparin protocol initiation was end anesthesia time until initiation of
AF/stroke prophylaxis protocol. When patients were transitioned from fixed dose
heparin to AF/stroke prophylaxis protocol, both heparin rate immediately preceding
transitioning to protocol and heparin rate (units/kg/hr) were recorded. In addition
to time in therapeutic range (TTR), we also assessed time subtherapeutic and
supratherapeutic defined as aPTT ranges of 0 to 59.9 and 80.1 to 200.1,
respectively. We also recorded percentage of aPTT tests within range, time from
protocol initiation to first therapeutic aPTT value and heparin rate at the time of first
therapeutic value. Percentage of time subtherapeutic, therapeutic, and
supratherapeutic were evaluated utilizing a modified version of the Rosendaal
method which assesses percentage of aPTT values in range.14
Survival, thrombosis and bleeding outcomes were also evaluated. Bleeding
events were assessed during heparin therapy and up to 48 hours after its
discontinuation with an event being defined as an episode of internal or external
bleeding leading to death, reoperation, permanent injury, or necessitating
transfusion of more than 2 units of blood within a consecutive 24 hour periods. To
be classified as a bleeding event, patients were required to be actively on the
specified heparin protocol. Thrombosis endpoints were assessed from initiation of
heparin therapy until the end of the study analysis. Thrombosis endpoints
included thrombus formation within the device or systemic events including
cardioembolic stroke, thrombotic stroke/transient ischemic attack, myocardial
infarction, deep vein thrombosis (DVT) or pulmonary embolism (PE). All events
were assessed through review of medical records, including progress, surgical,
and radiographic reports.

Results
During the study time frame a total of 135 patients underwent LVAD implantation
with 62 patients meeting the implanting group inclusion criteria. Patients were
excluded for the following reasons: achieved therapeutic aPTT on fixed dose
heparin (n=26), utilized bivalirudin for anticoagulation (n=14), only received fixed
dose heparin (n=9), did not receive anticoagulation (n=8) were not initiated on
standard protocol (n=8), received less than24 hours of heparin (n=1). Of the eight
patients excluded from the analysis due to LVAD pump exchange four of the
exchanges were the result of LVAD thrombosis. Further evaluation identified that
only one of the four device thrombosis were previously on the AF/stroke
prophylaxis heparin protocol. A total of 52 patients who were readmitted and
initiated on heparin protocol and included in the readmission cohort.
Baseline demographics are reported for patients included within both cohorts.
(Table 1) Patients were predominately male (initial: 84% and re-implant: 94.2%)
who were more likely to be implanted with HeartMate II (initial: 80.6% and reimplant: 80.8%) as compared to Heartware (initial: 19.4% and re-implant: 19.2%).
Large discrepancies were noted between actual body weight and adjusted body
weight within both cohorts.
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Table 1. Baseline Demographics
Baseline Demographics

Initial Implant

Readmission

(n=62)

(n=52)

54.2 years (27-73.8)

53.9 years (28.271.3)

54 (87%)

49 (94.2%)

24 (38.7%)
25 (40%)
13 (20.1%)

24 (46.2%)
14 (26.9%)
14 (26.9%)

Weight

96.3 kg (53.8-180)

101.7 kg (67.5179.6)

Heparin dosing weight

83.5 kg (56-133.5)

82.5 kg (58.0-123)

Age

Gender (male)
Race
Caucasian
African American
Other

Indication for LVAD
Ischemic Cardiomyopathy
Non-Ischemic Cardiomyopathy

37 (59.7%)
25 (40.3%)

Type of LVAD
Heartmate II
HVAD

50 (80.6%)
12 (19.4%)

Comorbidities
Diabetes mellitus
Atrial Fibrillation
Respiratory Failure
Renal Failure
Liver failure
Other

21 (36%)
20 (32.3%)
9 (14.5%)
21 (36%)
5 (8.1%)
32 (51.6%)

42 (80.8%)
10 (19.2%)

Kg = kilogram; LVAD = left ventricular assist device;
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Within the initial implantation cohort, 93.5% (n=58) of patients were discharged
from the hospital while 4% required pump exchange or died. (Table 2) A total of 8
patients (12.9%) developed thrombus formation which was confirmed by radiologic
studies at a subsequent point following LVAD implantation. Bleeding events were
demonstrated in 17.7% (n=11) of patients while receiving heparin.
Table 2. Outcomes following initial implantation
Outcomes – Initial Implantation

(n=62)

Survival
Discharge from hospital
Pump exchange
Death

58 (93.5%)
2 (3.2%)
2 (3.2%)

Thrombus

8 (12.9%)

Bleeding

11 (17.7%)

Blood product utilization, median (Range)
Red Blood Cell
Fresh Frozen Plasma
Platelet
Cryoprecipitate

6 (0-23)
3 (0-12)
2 (0-8)
0 (0-4)

Factor administration, n (%)

1 (2%)

During initial LVAD implantation, heparin was initiated an average of 32.6 hours
following completion of end anesthesia time. (Table 3) Patients were initiated on
protocol heparin nearly 64 hours later with average conversion of heparin rate from
667.2 units/hr (100-1800) to 12.8 units/kg/hr (6-22). An additional 32 hours was
required from initiation of heparin protocol for patients to achieve their 1st
therapeutic aPTT with an average heparin rate of 17 units/kg/hr. Overall, patients
were within therapeutic range 40% of the time during the initial implantation cohort.
(Table 3) When patients weren’t therapeutic they were more frequently noted to be
subtherapeutic (37.9%) as compared to supratherapeutic (16.7%).
With respect to the readmission cohort, numerically, there was a similar protocol
initiation rate (13.6 units/kg/hr) and heparin rate at 1st therapeutic aPTT value (16.7
units/kg/hr) but patients achieved therapeutic aPTT nearly 3 hours earlier. Despite
this TTR was essentially unchanged at 44.2%. (Table 3) Overall, patients were
considered supratherapeutic only 13.2% of the time.
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Table 3. Anticoagulation outcomes
Anticoagulation

Initial Implantation

Readmission

(n=62)

(n=52)

Heparin initiation – post implant hours

32.6 (7.4-140.5)*

N/A

Heparin protocol initiation – post implant hours

96.2 (14.6-267.3)

N/A

Heparin rate prior to protocol conversion
units/hour

667.2 (100-1800)+

N/A

12.8 (6-22)

13.6 (7 – 16)

32.3 (2.9-86)¥

29.0 (5.3 –
93.7)¥

17 (6-26)

16.7 (11 - 24)

Hours in range (% of time)
Subtherapeutic (0 - < 60)
Therapeutic (60 – 80)
Supratherapeutic (>80 – 200)

37.9 (0 – 100)
40.4 (0 – 85.2)
16.7 (0 – 37.9)

41.8 (6.7 – 84.2)
44.2 (0 – 100)
13.2 (0 – 37.1)

aPTT tests in range (% of time)
Subtherapeutic (0 - < 60)
Therapeutic (60 – 80)
Supratherapeutic (>80 – 200)

41.9 (0 – 100)
34.7 (0 – 75)
19.8 (0 – 40)

46.4 (16.7 –
87.5)
39.9 (0 – 100)
14.3 (0 – 30.8)

Protocol initiation rate units/kg/hour
Hours to 1st therapeutic aPTT (from protocol
initiation)
Heparin rate at 1st therapeutic aPTT units/kg/hour

aPTT = activated partial thromboplastin time;
* 4 patients were not initiated on fixed dose heparin
+
4 patients not initiated on fixed dose heparin; unable to equate fixed rate prior to
protocol initiation
¥
2 patients (initial) and 1 patient (readmission) did not achieve therapeutic aPTT
prior to heparin discontinuation
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Regarding maintenance of therapeutic anticoagulation following achieving a
therapeutic aPTT value the cohorts were nearly identical with 48.8% in the initial
implantation and 52.3% in the readmission cohorts, respectively. (Table 4)
Table 4. Time in therapeutic range once patient reaches first therapeutic
aPTT

% hours within range
% of tests in range

Initial Implantation

Readmission

(n=50)+

(n=52) *

48.8 (0-96.9)

53.9 (14.4 – 100)

42.7 (0-75)

50.2 (0 – 100)

+

2 patient did not achieve therapeutic aPTT and time in therapeutic range was not
calculated
*

1 patient did not achieve therapeutic aPTT and time in therapeutic range was not
calculated

Discussion
Our analysis demonstrated that patients were supratherapeutic following LVAD
implantation only 16.7% of the time, likely owing to ongoing bleeding concern
following implantation. Despite overall totality of therapeutic heparin being 40%,
after achieving a therapeutic aPTT the ongoing TTR only increased to 48.8%.
Even with a relatively low TTR, the subsequent risk of thrombus (12.9%) was
similar, albeit on the higher side, to what has been demonstrated in published
literature.15,16 Patients were separated into two distinct groups as they represent
vastly different management strategies. Patients who are immediately postoperative are at much higher bleeding risk, and careful consideration of
anticoagulation must be taken. Patients being readmitted on the other hand, are
potentially at a higher risk of thrombus formation and might require more
aggressive anticoagulation management. Of the eight patients excluded from the
analysis due to LVAD exchange, four were the result of device thrombosis but only
one of the thrombosed devices previously received the evaluated protocol. As this
was a descriptive, retrospective study assessing effectiveness of the heparin
protocol to achieve and maintain therapeutic anticoagulation establishing a causal
relationship to development of thrombosis was not possible.
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The use of LVAD therapy has significantly improved the life span of advanced
heart failure patients serving as destination therapy or as bridge to transplant, it is
not without complications.1-5; 17 The optimal LVAD will provide cardiac support to
heart failure patients while eliminating the need for a driveline, and reducing or
eliminating the risk for thrombotic and bleeding events. Vast strides have been
made to further advance the pump design and with improved technology these
complications may become obsolete.17 As pump technology continues to evolve
optimization of anticoagulation and antiplatelet therapy has been shown to reduce
the rate of pump thrombosis up to 50%.18 To capitalize on these findings the
PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management
(PREVENT) study was designed to establish whether a standardize approach for
surgical implant technique, anticoagulation, and pump speeds following HMII
implantation would reduce the risk of pump thrombosis. Full adherence to implant
techniques, anticoagulation and pump speeds significantly reduced the risk of
pump thrombosis (1.9% vs. 8.9%; p <0.01) and the composite outcome
(suspected thrombosis, hemolysis, and ischemic stroke) at 6 months (5.6% vs
17.7%; p<0.01).19 Despite, the significant benefit noted with full adherence to key
recommendations overall, the recommendations were inconsistently followed with
78% adherence to surgical recommendations, 95% to heparin bridging, and 79%
to pump speeds >=9,000 RPMs.19
It is difficult to determine whether a specific recommendation from the PREVENT
study had an impact on reduction in pump thrombosis as the study was not
powered to assess individual components effect on pump thrombosis. It could be
argued that the anticoagulation and antiplatelet recommendations within
PREVENT be strictly followed. The median INR within the analysis was 2.1 (IQR
1.9-2.3) but median time spent at a target range (2.0-2.5) was only 31% (IQR
19%-44%).19 Unfortunately, a protocol for achieving and maintaining specific
aPTT values was not discussed by the study investigators and the results
regarding time within therapeutic range of heparin were not reported.
Raschke et al. produced a landmark study demonstrating that heparin dosing
based on patients’ body weight resulted in more rapid anticoagulation as well as
fewer recurrent thrombotic events when compared to “standard care” nomogram.20
In an effort to advance heparin anticoagulation, Schlicht et al. compared the
Raschke nomogram with an institution-specific modified nomogam to achieve
therapeutic aPTTs. The authors were able to demonstrate a reduction in time to
achieve therapeutic aPTT’s while simultaneously reducing the risk of over
anticoagulation (as evaluated based on aPTT values >90 secs).21 It should be
noted that the Raschke nomogram was built on the premise of rapidly achieving
aPTTs of 1.5-2.5 times the control which may not be appropriate for all heparin
indications and modification of institutional protocols based on indications may
help optimize anticoagulation.
Despite protocol development through titration to specific anticoagulant markers,
little data exists on how effective protocols are at maintaining therapeutic
anticoagulation. Kim et al. tried to demonstrated the effectiveness of
unfractionated heparin through assessment of achieving and maintain therapeutic
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aPTT as well as adequacy of the hospital nomogram.22 Their results demonstrated
a high percentage of patients achieving a therapeutic range at 24 hours (69.5%;
n=91) and 48 hours (90.1%; n=18) with a therapeutic aPTT proportion of only
39.2%.
Aarab et al. evaluated UFH in critically ill patients requiring anticoagulation for a
variety of indications.23 Time to therapeutic range was 24 hours in 56% of the 101
patients admitted to the ICU and medium care unit. The results within the current
analysis demonstrated that irrespective of the cohort the overall time within
therapeutic range was less than 50%. Additionally, following the first therapeutic
aPTT value, irrespective of the group, the time in therapeutic range was only
approximately 50%. Several centers have reported heparin protocol development
for use in various MCS devices but to our knowledge there hasn’t been a study
discussing effectiveness of individual protocols within the LVAD population.24-26
One of the difficulties with utilizing aPTT values to assess for heparin effectiveness
relates to the broadness of the aPTT test. There are a variety of disease states
and factors that can influence the aPTT value, many of which are seen within the
advanced heart failure and LVAD population.27 In fact, the aPTT test provides a
better representation of overall coagulopathy as opposed to heparin concentration.
Our study showed that patients were within therapeutic range only 40.4% of the
time with only 34.7% of aPTT values being therapeutic. Somewhat surprisingly,
there was not a noticeable difference in time within therapeutic range 44.2% with
only 39.9% of tests within range in the readmission cohort. Upon achieving a
therapeutic aPTT maintenance of therapeutic anticoagulation was only
demonstrated 50% of the time, irrespective of cohort analyzed. These data
suggest that while significant improvements can be made with heparin monitoring
and dosing, they are consistent to previously reported heparin protocols.22,,23 The
use of anti-factor Xa levels for monitoring systemic heparin anticoagulation has
been discussed as a better marker for heparin effect on anticoagulation.28 Several
studies, outside the MCS population, have demonstrated less dose titrations and
more consistent anticoagulation with the anti-factor Xa test.29-31 Additionally, with
mechanical circulatory devices patients, it has been reported that there exists a
significant discordance between the two monitoring tests which raises the question
of which should be utilized to adjust and monitor heparin.32 In a patient population
with potential ongoing coagulopathy, the use of a sole marker to monitor
anticoagulation may negatively impact patient care and predispose patients to
bleeding or thrombotic events. Further research is required to elucidate the best
monitoring strategy in a very dynamic patient population.
There are several limitations of this study that merit mentioning including the
retrospective nature of the design. First, while the authors tried to develop a study
protocol that objectively assessed patient management through defining heparin
protocol procedures, the analyses are limited by the retrospective nature of the
study and the reliance of documentation by the medical team. Additionally, patient
management strategies could evolve based on physician experience (presenting a
historical bias) or could change based on clinical scenario. These factors provide
a potential confounder if included, as changes in protocol could be the result of
increased bleeding or thrombosis risk leading the clinician to modify therapeutic
targets. The authors felt that the retrospective nature of the study and reliance on
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documentation prevented a clear association between protocol changes and
rationale behind changes. Therefore, in an effort to eliminate this limitation, the
authors chose to exclude patients who had protocol modifications. It is important
to note that individual patients may require different degrees of heparin if they are
at higher or lower risk for bleeding and a single protocol may not be suitable for all
LVAD patients. The fact that 73 patients were excluded for various reasons
speaks to the overall heterogeneity within this patient population, especially with
respect to INTERMACS score at time of implantation and risk for post-operative
complications.
Secondly, the authors did not include the average pump speed or range of pump
speed, which has been associated with outcomes. The authors felt that without a
prospective protocol in place the association between pump speeds and heparin
anticoagulation would be difficult to address. Further, due to a potential change in
management practice as a result of patient inclusion into the PREVENT study, we
did not feel this information would be beneficial.
Finally, as the primary emphasis of this study was to evaluate the effectiveness of
the AF/stroke prophylaxis heparin protocol on achieving and maintaining
therapeutic anticoagulation, assessment of differing protocols on clinical outcomes
was not possible. Given the small sample size of this analysis, a direct
comparison would unlikely be powered to distinguish any differences in outcomes.
However, this analysis should be utilized as a starting point for subsequent
analyses addressing the question of how differences in heparin protocols may
influence clinical outcomes.

Conclusion
Patients initiated on heparin atrial fibrillation and stroke prevention protocol only
achieved therapeutic anticoagulation approximately 40% of the time. Even after
patients achieved a therapeutic aPTT, time in therapeutic range was only 48.7%;
however, despite these seemingly low values the demonstrated risk of thrombosis
was similar to published literature. Individual centers should perform ongoing
assessment of effectiveness of individual heparin protocol for LVAD to ensure
anticoagulation is optimized in these highly complex patients.
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